Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study

Monday, June 6, 2016
Cover of Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study
Karen Clements, ScD
University of Massachusetts Medical School
Kimberly Lenz, PharmD
University of Massachusetts Medical School
Paul L. Jeffrey, PharmD
University of Massachusetts Medical School
Pavel Lavitas, PharmD, BCPS
University of Massachusetts Medical School
Parag Kunte, MPH
University of Massachusetts Medical School
Elizabeth O’Connell, MS
University of Massachusetts Medical School

Regimens that contain sofosbuvir (SOF) or simeprevir (SIM) are highly effective for treating chronic hepatitis C virus (HCV) infection. These regimens, however, are expensive. Most payers have implemented prior authorization (PA) requirements to ensure that patients who can benefit most have priority for these medications. While many Medicaid programs limit access to those with advanced disease or to members who do not have active substance use disorder (SUD), the Massachusetts Medicaid (MassHealth) Primary Care Clinician (PCC) plan does not limit access based on disease severity or presence of SUD. Evaluating PA requests for SOF and/or SIM among MassHealth members will offer a useful example of early uptake among Medicaid members and will identify patient groups who might face barriers to treatment at the provider or patient level.

The study concludes that antiviral treatment with SOF and/or SIM was requested for a relatively small proportion of MassHealth members with HCV, with nearly all approved. Prescriber prioritization or patient barriers to care, rather than the PA process, determined access to treatment in this Medicaid population. Support may be needed to ensure patients with SUD benefit from advances in HCV treatment.